Status:
COMPLETED
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rhe...
Eligibility Criteria
Inclusion
- Diagnosis of RA or PsA
- ≥18 years at index treatment initiation
- Participants starting treatment with:
- abatacept
- non-targeted DMARDs
- targeted DMARD
Exclusion
- \- Not applicable
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2025
Estimated Enrollment :
140706 Patients enrolled
Trial Details
Trial ID
NCT05413044
Start Date
July 1 2019
End Date
October 31 2025
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Princeton, New Jersey, United States, 08540